PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)

Overview of attention for article published in Retina, December 2011

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 363 followers.

[VEGF] Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevac... http://t.co/jTpZwGBj PM

[VEGF] PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVAC... http://t.co/hAG5H9Uo PM

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.